ALIBABA-GROUP
11.6.2019 06:02:07 CEST | Business Wire | Press release
Alibaba A.I. Labs, an AI research division of Alibaba Group, today announced at CES Asia partnerships with auto brands, including Audi, Renault and Honda to drive a smart mobility initiative in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005833/en/
Tmall Genie Auto, an Artificial Intelligence solution developed by Alibaba A.I. Labs, will be integrated into the automakers’ specific internet cars in China.
Owners of the three auto brands’ specific-model vehicles equipped with Tmall Genie Auto will have access to a wide variety of voice-controlled information and services in the near future; these include identifying nearby attractions and restaurants, booking movie tickets, ordering to-go boxes, checking the status of package deliveries, reading children’s books and ordering items on Alibaba’s retail platform.
In addition, car owners with a Tmall Genie-compatible device at home would be able to monitor and control their smart-home devices from their cars in the near future, performing daily tasks such as running a status check on temperature and light, or turning on the heater and air conditioning at home.
“By providing AI technologies, including speech-recognition and Natural Language Processing, Tmall Genie Auto enables car users to access an extensive in-car infotainment portfolio by tapping into Alibaba’s rich content and service ecosystem,” said Miffy Chen, General Manager at Alibaba A.I. Labs . “We are thrilled to partner with global distinguished auto brands such as Audi, Renault and Honda. Together, we can greatly enhance our in-car services and make driving experience more intelligent and interconnected.”
“We aim to extend in-car voice assistant services according to the demands and needs of our Chinese customers,” said H.W. Vassen, Senior Director of Digitalization and NEV Development at Audi China . “To do so, one of our next steps is to intensity the cooperation with Alibaba Tmall Genie.”
Guillaume SICARD, Vice President of Sales and Marketing, Region China, Groupe Renault , commented: “The launch of the Renault City K-ZE Tmall Genie Edition allows consumers to experience a deeper connection between scenarios in their lives at home and their lives on the go. It is also a manifesto that DRAC and Tmall will continue to maintain profound cooperation on areas such as brand marketing, potential customer mining and sales network enablement, in order to achieve new breakthroughs.”
Hasegawa Yusuke, the Executive Vice President of Honda Motor (China) Investment Co., Ltd , said: “The world’s mobility industries are currently undergoing a major transformation. Our mobility and daily lives will finally enter into the era of Internet for Everything, Honda has been actively embracing the trend of electrification and ICVs, and accelerating the advancement of the third-generation Honda CONNECT system which includes the Smart AI function. We look forward to working with Alibaba A.I. Labs on creative initiatives by leveraging the AI technology and Alibaba’s diverse ecosystem services.”
During CES Asia, Alibaba’s B2C marketplace Tmall also announced its tie-up with Renault to roll out an electric car featuring Tmall’s iconic cat logo on the vehicle’s exterior design. The Renault City K-ZE genie edition, also integrated with Tmall Genie Auto, will be on sale in China later this year.
Tmall Genie is the bestselling smart speaker in China. Today it can control over 100 million devices from over 600 smart appliance brands, offering its Internet of Things ecosystem capabilities to various sectors and user environments from home, car, hotels to nursing homes.
Alibaba A.I. Labs spearheads consumer AI product development at Alibaba Group. Since the launch of Tmall Genie Auto solution last April, Alibaba A.I. Labs has also partnered with auto brands including BMW and Volvo Cars to provide intelligent and connected mobility experiences for consumers in China.
About Alibaba A.I. Labs
Alibaba A.I. Labs is dedicated to exploring the next-generation human-and-computer interaction and turning novel user experience into reality. The in-house R&D department focuses on the development of innovative AI applications across Alibaba’s commerce ecosystem and provides AI solutions to Alibaba’s clients and partners. With a world-class research team, Alibaba A.I. Labs focuses on both theoretical research and product commercialization in various areas, including speech recognition, natural language processing, voice print identification, deep learning, and computer vision. The Labs also focuses on developing AI products for consumers, including Tmall Genie, the first voice- controlled smart home assistant developed by the Labs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005833/en/
Contact:
Crystal Liu Alibaba Group +86 18578497650/+852 6378 5626 Crystal.liu@alibaba-inc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom